USA - engelsk - NLM (National Library of Medicine)

dispensing solutions, inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug - serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in patients aged 4 years and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. laba, such as salmeterol, the active ingredient in serevent diskus, increase the risk of asthma-related death [see warnings and precautions (5.1)] . use of serevent diskus for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated [see contraindications (4)] . use serevent diskus only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue sere

USA - engelsk - NLM (National Library of Medicine)

glaxosmithkline llc - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug - serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with an ics in patients aged 4 years and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. laba, such as salmeterol, the active ingredient in serevent diskus, as monotherapy (without ics) increase the risk of asthma-related death [see warnings and precautions (5.1)] . use of serevent diskus for the treatment of asthma without concomitant use of an ics is contraindicated [see contraindications (4)] . use serevent diskus only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ics. do not use serevent diskus for patients whose asthma is adequately controlled on low- or medium-dose ics. pediatric and adolescent patients available data from controlled clinical trials suggest that laba as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent pati

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - salmeterolum xínafóat - innöndunarduft - 50 míkróg/skammt

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol;   - powder for inhalation - 50 mcg/dose - active: salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol   excipient: lactose monohydrate - serevent is indicated for long-term regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise-induced asthma) in adults and children who are receiving inhaled or oral corticosteroids. serevent should be used only as an adjunct to corticosteroids in the management of asthma. serevent should not be used in the treatment of acute asthmatic symptoms, or in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists.

Serbia - serbisk - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

evropa lek pharma d.o.o. beograd - Салметерол - suspenzija za inhalaciju pod pritiskom - 25mcg/doza

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

glaxosmithkline gmbh & co. kg (8041694) - salmeterolxinafoat - einzeldosiertes pulver zur inhalation - salmeterolxinafoat (26167) 0,0725 milligramm

Irland - engelsk - HPRA (Health Products Regulatory Authority)

ltt pharma limited - salmeterol xinafoate - pressurised inhalation suspension - 25 microgram - selective beta-2-adrenoreceptor agonists - selective beta-2-adrenoreceptor agonists - it is indicated for the regular symptomatic add-on treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma, who are inadequately controlled on inhaled corticosteroids in accordance with current treatment guidelines. serevent is also indicated in the prevention of exercise-induced asthma

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - salmeterolum - multidosen-inalatore a polvere - salmeterolum 50 µg per salmeteroli xinafoas, lactosum monohydricum a polvere per dosi. - bronchospasmolytikum - synthetika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - salmeterolum - dosier aerosol - salmeterolum 25 µg di salmeteroli xinafoas, norfluranum per aerosolum per le dosi. dosi per la nave 120. - bronchospasmolytikum - synthetika

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

glaxosmithkline s.a. - salmeterol xinafoato - suspensiÓn para inhalaciÓn en envase a presiÓn - 25 microgramos/dosis - salmeterol xinafoato 25 microgramos - salmeterol